The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: A review

European Journal of Pharmacology

Volumn 463, Issue 1-3, 2003, Pages 3-33

  Prut, Laetitia ^a   Belzung, Catherine ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

5 HT (5 hydroxytryptamine: serotonin); Anxiety; Benzodiazepine; Neuropeptide; Open field

Indexed keywords

3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; 3 METHYL 6 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; 3 METHYLFLUNITRAZEPAM; 3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4' CHLORODIAZEPAM; 8 AZIDO 5,6 DIHYDRO 5 METHYL 6 OXO 4H IMIDAZO[1,5 A][1,4]BENZODIAZEPINE 3 CARBOXYLIC ACID ETHYL ESTER; ABECARNIL; ADINAZOLAM; ALPIDEM; ALPRAZOLAM; ANXIOLYTIC AGENT; BARBITOL; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BETA CARBOLINE 3 CARBOXYLIC ACID; BICUCULLINE; BRETAZENIL; BROTIZOLAM; CHLORDIAZEPOXIDE; CLONAZEPAM; CROTOXIN; DELORAZEPAM; DIAZEPAM; DORAMECTIN; ESTAZOLAM; ETHANOLAMINE SULFATE; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; NERISOPAM; NORDAZEPAM; PRASTERONE; PRASTERONE SULFATE; RO 15 1812; RO 19 8022; RY 008; SEROTONIN 1A AGONIST; SEROTONIN UPTAKE INHIBITOR; SKF 89976 A; TRIAZOLOBENZODIAZEPINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY; ANXIETY DISORDER; DRUG EFFICACY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OPEN FIELD TEST; PANIC; PRIORITY JOURNAL; REVIEW;

EID: 0037470154     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01272-X     Document Type: Review

References (185)

1. Adams P.M. Effects of perinatal chlordiazepoxide exposure on rat preweaning and postweaning behavior. Neurobehav. Toxicol. Teratol. 4:1982;279-282.
2. Ågmo A., Pruneda R., Guzman M., Gutierrez M. GABAergic drugs and conflict behavior in the rat: lack of similarities with the actions of benzodiazepines. Naunyn-Schmiedeberg's Arch. Pharmacol. 344:1991;314-322.
3. 1A receptor agonists flesinoxan and 8-OH-DPAT in the rat. Eur. J. Pharmacol. 200:1991;259-266.
4. Alleva E., Laviola G., Tirelli E., Bignami G. Short-, medium-, and long-term effects of prenatal oxazepam on neurobehavioural development of mice. Psychopharmacology. 87:1985;434-441.
5. Andersen I., Faerevik G., Boe K.E., Janczak A.M., Bakken M. Effects of diazepam on the behavior of weaned pigs in three putative models of anxiety. Appl. Anim. Behav. Sci. 68:2000;121-130.
6. Angrini M., Leslie J.C., Shephard R.A. Effects of propranolol, buspirone, pCPA, reserpine, and chlordiazepoxide on open-field behavior. Pharmacol. Biochem. Behav. 59:1998;387-397.
7. Barros H.M., Tannhauser S.L., Tannhauser M.A., Tannhauser M. The effects of GABAergic drugs on grooming behaviour in the open field. Pharmacol. Toxicol. 74:1994;339-344.
8. Bast T., Zhang W.N., Feldon J. Hyperactivity, decreased startle reactivity, and disrupted prepulse inhibition following disinhibition of the rat ventral hippocampus by the GABA(A) receptor antagonist picrotoxin. Psychopharmacology (Berl.). 156:2001;225-233.
9. Bast T., Zhang W.N., Feldon J. The ventral hippocampus and fear conditioning in rats. Different anterograde amnesias of fear after tetrodotoxin inactivation and infusion of the GABA(A) agonist muscimol. Exp. Brain Res. 139:2001;39-52.
10. Beaufour C.C., Le Bihan C., Hamon M., Thiebot M. Extracellular dopamine in the rat prefrontal cortex during reward-, punishment- and novelty-associated behaviour. Effects of diazepam. Pharmacol. Biochem. Behav. 69:2001;133-412.
11. Beckett S.R., Lawrence A.J., Marsden C.A., Marshall P.W. Attenuation of chemically induced defence response by 5-HT1 receptor agonists administered into the periaqueductal gray. Psychopharmacology (Berl.). 108:1992;104-110.
12. Belzung C. Measuring exploratory behavior. Crusio W.E., Gerlai R.T. Handbook of Molecular Genetic Techniques for Brain and Behavior Research (Techniques in the Behavioral and Neural Sciences). 1999;739-749 Elsevier, Amsterdam.
13. Belzung C. Rodent models of anxiety-like behaviors: are they predictive for compounds acting via non-benzodiazepine mechanisms? Curr. Opin. Investig. Drugs. 2:2001;1108-1111.
14. Belzung C., Berton F. Further pharmacological validation of the Balb/c neophobia in the free exploratory paradigm as an animal model of trait anxiety. Behav. Pharmacol. 8:1997;541-548.
15. Belzung C., Griebel G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav. Brain Res. 125:2001;141-149.
16. Belzung C., El Hage W., Moindrot N., Griebel G. Behavioral and neurochemical changes following predatory stress in mice. Neuropharmacology. 41:2001;400-408.
17. Belzung C., Griebel G., Dubois-Carmagnat F., Darves-Bornoz J.M. Amino acid transmitter systems. D'Haenen H., den Boer J.A., Willner P. Biological Psychiatry. 2002;915-927 Wiley, Chichester, England.
18. Bert B., Fink H., Sohr R., Rex A. Different effects of diazepam in Fischer rats and two stocks of Wistar rats in tests of anxiety. Pharmacol. Biochem. Behav. 70:2001;411-420.
19. Bhattacharya S.K., Clow A., Przyborowska A., Halket J., Glover V., Sandler M. Effect of aromatic amino acids, pentylenetetrazole and yohimbine on isatin and tribulin activity in rat brain. Neurosci. Lett. 132:1991;44-46.
20. Bhattacharya S.K., Sen A.P., Upadhyay S.N., Jaiswal A.K. Anxiolytic activity of piracetam, a nootropic agent, following subchronic administration in rodents. Indian J. Exp. Biol. 31:1993;902-907.
21. Bhattacharya S.K., Chakrabarti A., Sandler M., Glover V. Anxiolytic activity of intraventricularly administered atrial natriuretic peptide in the rat. Neuropsychopharmacology. 15:1996;199-206.
22. Bhattacharya S.K., Bhattacharya A., Ghosal S. Anxiogenic activity of methylenedioxymethamphetamine (Ecstasy): an experiment study. Biog. Amine. 14:1998;217-237.
23. Bitran D., Shiekh M., Dowd J.A., Dugan M.M., Renda P. Corticosterone is permissive to the anxiolytic effect that results from the blockade of hippocampal mineralocorticoid receptors. Pharmacol. Biochem. Behav. 60:1998;879-887.
24. Boerngen-Lacerda R., Souza-Formigoni M.L. Does the increase in locomotion induced by ethanol indicate its stimulant or anxiolytic properties? Pharmacol. Biochem. Behav. 67:2000;225-232.
25. Borsini F., Giuliani S., Meli A. Functional responses to baclofen and 4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-ol (THIP) in rats repeatedly treated with desipramine. Pharmacol. Biochem. Behav. 29:1988;189-191.
26. Britton D.R., Britton K.T. A sensitive open field measure of anxiolytic drug activity. Pharmacol. Biochem. Behav. 15:1981;577-582.
27. Britton D.R., Indyk E. Central effects of corticotropin releasing factor (CRF): evidence for similar interactions with environmental novelty and with caffeine. Psychopharmacology (Berl.). 101:1990;366-370.
28. Britton D.R., Koob G.F., Rivier J., Vale W. Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci. 31:1982;363-367.
29. Broderick P.A., Hope O., Jeannot P. Mechanism of triazolo-benzodiazepine and benzodiazepine action in anxiety and depression: behavioral studies with concomitant in vivo CA1 hippocampal norepinephrine and serotonin release detection in the behaving animal. Prog. Neuropsychopharmacol. Biol. Psychiatry. 22:1998;353-386.
30. Bruhwyler J. Anxiolytic potential of a microgram dose of chlordiazepoxide in the open-field test. Eur. J. Pharmacol. 187:1990;547-549.
31. Bruhwyler J., Chleide E., Houbeau G., Mercier M. Stimulant effect of the beta-carboline FG 7142 in the open-field test. Eur. J. Pharmacol. 200:1991;183-185.
32. Bruijnzeel A.W., Stam R., Wiegant V.M. Effect of a benzodiazepine receptor agonist and corticotropin-releasing hormone receptor antagonists on long-term foot-shock-induced increase in defensive withdrawal behavior. Psychopharmacology (Berl.). 158:2001;132-139.
33. Cannizzaro C., Martire M., Cannizzaro E., Provenzano G., Gagliano M., Carollo A., Mineo A., Steardo L. Long-lasting handling affects behavioural reactivity in adult rats of both sexes prenatally exposed to diazepam. Brain Res. 904:2001;225-233.
34. Car H., Kuziemka L., Eska M., Wisniewski K. The NMDA and GABA-A receptors in behavioral activity of rats. Acta Physiol. Hung. 84:1996;269-270.
35. Carli M., Prontera C., Samanin R. Effect of 5-HT1A agonists on stress-induced deficit in open field locomotor activity of rats: evidence that this model identifies anxiolytic-like activity. Neuropharmacology. 28:1989;471-476.
36. Carli M., Tatarczynska E., Cervo L., Samanin R. Stimulation of hippocampal 5-HT1A receptors causes amnesia and anxiolytic-like but not antidepressant-like effects in the rat. Eur. J. Pharmacol. 234:1993;215-221.
37. Chesley S., Lumpkin M., Schatzki A., Galpern W.R., Greenblatt D.J., Shader R.I., Miller L.G. Prenatal exposure to benzodiazepine: I. Prenatal exposure to lorazepam in mice alters open-field activity and GABAA receptor function. Neuropharmacology. 30:1991;53-58.
38. Choleris E., Thomas A.W., Kavaliers M., Prato F.S. A detailed ethological analysis of the mouse open field test: effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field. Neurosci. Biobehav. Rev. 25:2001;235-260.
39. Clement Y., Calatayud F., Belzung C. Genetic basis of anxiety-like behaviour: a critical review. Brain Res. Bull. 57:2002;57-71.
40. Coscina D.V., Nobrega J.N. Effects of lateral hypothalamic lesions on the anorexia induced by ethanolamine-O-sulfate. Pharmacol. Biochem. Behav. 32:1989;275-281.
41. Crawley J.N. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol. Biochem. Behav. 15:1981;695-699.
42. Czlonkowska A.I., Sienkiewicz-Jarosz H., Siemiatkowski M., Bidzinski A. The effects of neurosteroids on rat behavior and 3H-muscimol binding in the brain. Pharmacol. Biochem. Behav. 63:1999;639-646.
43. Daugé V., Dor A., Feger J., Roques B.P. The behavioral effects of CCK8 injected into the medial nucleus accumbens are dependent on the motivational state of the rat. Eur. J. Pharmacol. 163:1989;25-32.
44. De Angelis L. Experimental anxiety and antidepressant drugs: the effects of moclobemide, a selective reversible MAO-A inhibitor, fluoxetine and imipramine in mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 354:1996;379-383.
45. De Angelis L., Bertolissi M., Nardini G., Traversa U., Vertua R. Interaction of caffeine with benzodiazepines: behavioral effects in mice. Arch. Int. Pharmacodyn. Ther. 255:1982;89-102.
46. Delini-Stula A., Hunn C. Differential effects of anxiolytics and beta-receptor blocking drugs on novelty-oriented ("neophobic") behavior in the rat. Pharmacopsychiatry. 21:1988;186-191.
47. Depaulis A., Vergnes M. Elicitation of intraspecific defensive behaviors in the rat by microinjection of picrotoxin, a gamma-aminobutyric acid antagonist, into the midbrain periaqueductal gray matter. Brain Res. 367:1986;87-95.
48. De Souza Spinosa H., Gerenutti M., Bernardi M.M. Anxiolytic and anticonvulsant properties of doramectin in rats: behavioral and neurochemistric evaluations. Comp. Biochem. Physiol., Toxicol. Pharmacol. 127:2000;359-366.
49. Dringenberg H.C., Hargreaves E.L., Baker G.B., Cooley R.K., Vanderwolf C.H. p-Chlorophenylalanine-induced serotonin depletion: reduction in exploratory locomotion but no obvious sensory-motor deficits. Behav. Brain Res. 68:1995;229-237.
50. DSM-IV Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Pyschiatric Association, Washington, DC.
51. Durand M., Berton O., Aguerre S., Edno L., Combourieu I., Mormede P., Chaouloff F. Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic systems, and the corticotropic axis in SHR and WKY rats. Neuropharmacology. 38:1999;893-907.
52. Durand M., Aguerre S., Fernandez F., Edno L., Combourieu I., Mormede P., Chaouloff F. Strain-dependent neurochemical and neuroendocrine effects of desipramine, but not fluoxetine or imipramine, in spontaneously hypertensive and Wistar-Kyoto rats. Neuropharmacology. 39:2000;2464-2477.
53. Dwyer K.D., Roy E.J. Juvenile desipramine reduces adult sensitivity to imipramine in two behavioral tests. Pharmacol. Biochem. Behav. 45:1993;201-217.
54. Fahey J.M., Pritchard G.A., Grassi J.M., Pratt J.S., Shader R.I., Greenblatt D.J. Pharmacodynamic and receptor binding changes during chronic lorazepam administration. Pharmacol. Biochem. Behav. 69:2001;1-8.
55. Fahey J.M., Pritchard G.A., Pratt J.S., Shader R.I., Greenblatt D.J. Lorazepam attenuates the behavioral effects of dizocilpine. Pharmacol. Biochem. Behav. 62:1999;103-110.
56. Fernandez-Teruel A., Escorihuela R.M., Boix F., Tobena A. Picrotoxin changes the effects of imipramine and desipramine in rats in the forced swimming test. Eur. J. Pharmacol. 181:1990;35-41.
57. Ferre P., Escorihuela R.M., Tobena A., Fernandez-Teruel A. Evaluation of perinatal flumazenil effects on the behavior of female RLA/Verh rats in anxiety tests and shuttle box avoidance. Pharmacol. Biochem. Behav. 55:1996;475-480.
58. File S.E., Tucker J.C. Lorazepam treatment in the neonatal rat alters submissive behavior in adulthood. Neurobehav. Toxicol. Teratol. 5:1983;289-294.
59. Fiore M., Dell'Omo G., Alleva E., Lipp H.P. A comparison of behavioural effects of prenatally administered oxazepam in mice exposed to open-fields in the laboratory and the real world. Psychopharmacology (Berl.). 122:1995;72-77.
60. Fonseca N.M., Sell A.B., Carlini E.A. Differential behavioral responses of male and female adult rats treated with five psychotropic drugs in the neonatal stage. Psychopharmacologia. 46:1976;263-268.
61. Frye C.A., Lacey E.H. The neurosteroids DHEA and DHEAS may influence cognitive performance by altering affective state. Physiol. Behav. 66:1999;85-92.
62. Frye C.A., Sturgis J.D. Neurosteroids affect spatial/reference, working, and long-term memory of female rats. Neurobiol. Learn. Mem. 64:1995;83-96.
63. Gai N., Grimm V.E. The effect of prenatal exposure to diazepam on aspects of postnatal development and behavior in rats. Psychopharmacology. 78:1982;225-229.
64. Galpern W.R., Lumpkin M., Greenblatt D.J., Shader R.I., Miller L.G. Chronic benzodiazepine administration: VII. Behavioral tolerance and withdrawal and receptor alterations associated with clonazepam administration. Psychopharmacology. 104:1991;225-230.
65. Garcia-Gil L., De Miguel R., Romero J., Perez A., Ramos J.A., Fernandez-Ruiz J.J. Perinatal delta9-tetrahydrocannabinol exposure augmented the magnitude of motor inhibition caused by GABA(B), but not GABA(A), receptor agonists in adult rats. Neurotoxicol. Teratol. 21:1999;277-283.
66. Gentsch C., Lichteiner M., Feer H. Behavioral effects of yohimbine and chlordiazepoxide: dependence on the rat's previous familiarization with the test conditions. Neuropsychobiology. 22:1989;101-107.
67. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol. Ther. 65:1995;319-395.
68. Griebel G. Variability in the effects of 5-HT-related compounds in experimental models of anxiety: evidence for multiple mechanisms of 5-HT in anxiety or never ending story? Pol. J. Pharmacol. 48:1996;129-136.
69. 1A receptor blockers as potential drug candidates for the treatment of anxiety disorders. Drug News Perspect. 12:1999;484-490.
70. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol. Ther. 82:1999;1-61.
71. Griebel G., Blanchard D.C., Jung A., Lee J.C., Masuda C.K., Blanchard R.J. Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam. Neuropharmacology. 34:1995;1625-1633.
72. Griebel G., Perrault G., Sanger D.J. Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. Psychopharmacology. 131:1997;180-186.
73. Griebel G., Curet O., Perrault G., Sanger D.J. Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels. Neuropharmacology. 37:1998;927-935.
74. Grimaldi B., Bonnin A., Fillion M.P., Prudhomme N., Fillion G. 5-Hydroxytryptamine-moduline: a novel endogenous peptide involved in the control of anxiety. Neuroscience. 93:1999;1223-1225.
75. Guillamon A., Cales J.M., Rodriguez-Zafra M., Perez-Laso C., Caminero A., Izquierdo M.A., Segovia S. Effects of perinatal diazepam administration on two sexually dimorphic nonreproductive behaviors. Brain Res. Bull. 25:1990;913-916.
76. Hall C.S. Emotional behavior in the rat: I. Defecation and urination as measures of individual differences in emotionality. J. Comp. Psychol. 18:1934;385-403.
77. Handa R.J., George M., Gordon B.H., Campbell D.B., Lorens S.A. Responses to novelty stress in female F344 rats: effects of age and D-fenfluramine treatment. Pharmacol. Biochem. Behav. 53:1996;641-664.
78. Hard E., Engel J., Larsson K., Musi B. Effect of diazepam, apomorphine and haloperidol on the audiogenic immobility reaction and on the open field behavior. Psychopharmacology. 85:1985;106-110.
79. Harro J., Tonissaar M., Eller M., Kask A., Oreland L. Chronic variable stress and partial 5-HT denervation by parachloroamphetamine treatment in the rat: effects on behavior and monoamine neurochemistry. Brain Res. 899:2001;227-239.
80. Heilig M., Murison R. Intracerebroventricular neuropeptide Y suppresses open field and home cage activity in the rat. Regul. Pept. 19:1987;221-231.
81. Hiltunen A.J., Jarbe T.U. Discrimination of Ro 11-6896, chlordiazepoxide and ethanol in gerbils: generalization and antagonism tests. Psychopharmacology. 89:1986;284-290.
82. Horvath K., Andrasi F., Botka P., Hamori T. Anxiolytic profile of girisopam and GYKI 52,322 (EGIS 6775). Comparison with chlordiazepoxide and buspirone. Acta Physiol. Hung. 79:1992;153-161.
83. Hughes R.N. Effects on open-field behavior of diazepam and buspirone alone and in combination with chronic caffeine. Life Sci. 53:1993;1217-1225.
84. Huttunen P., Myers R.D. Tetrahydro-beta-carboline micro-injected into the hippocampus induces an anxiety-like state in the rat. Pharmacol. Biochem. Behav. 24:1986;1733-1738.
85. ICD-10, 1994. International Statistical Classification of Diseases and Related Health Problems (10th Revision). WHO Publications.
86. Jähkel M., Oehler J., Schumacher H.E. Influence of nootropic and antidepressive drugs on open field and running wheel behavior in spontaneously high and low active mice. Pharmacol. Biochem. Behav. 49:1994;263-269.
87. Jarbe T.U., Johansson J.O. Pentobarbital, diazepam and bemegride: their effects on open-field behavior in the gerbil (Meriones unguiculatus). Arch. Int. Pharmacodyn. Ther. 225:1977;88-97.
88. June H.L., Lewis M.J. Ro15-4513 enhances and attenuates motor stimulant effects of ethanol in rats. Alcohol. 6:1989;245-248.
89. June H.L., Johnson L.T., Lewis M.J. Ro15-4513 antagonizes depression of open-field horizontal activity by ethanol in rats. Alcohol. 6:1989;335-337.
90. June H.L., Cason C.R., Cheatham G., Lui R., Gan T., Cook J.M. GABAA-benzodiazepine receptors in the striatum are involved in the sedation produced by a moderate, but not an intoxicating ethanol dose in outbred Wistar rats. Brain Res. 794:1998;103-118.
91. Kask A., Rago L., Harro J. Anxiogenic-like effect of the NPY Y1 receptor antagonist BIBP3226 administered into the dorsal periaqueductal gray matter in rats. Regul. Pept. 75-76:1998;255-262.
92. Kask A., Vasar E., Heidmets L.T., Allikmets L., Wikberg J.E. Neuropeptide Y Y(5) receptor antagonist CGP71683A: the effects on food intake and anxiety-related behavior in the rat. Eur. J. Pharmacol. 414:2001;215-224.
93. Kemble E.D., Gibson B.M., Rawleigh J.M. Effects of eltoprazine hydrochloride on exploratory behavior and social attraction in mice. Pharmacol. Biochem. Behav. 38:1991;759-762.
94. Khisti R.T., Chopde C.T., Jain S.P. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol. Biochem. Behav. 67:2000;137-143.
95. Klodzinska A., Jaros T., Chojnacka-Wojcik E., Maj J. Exploratory hypoactivity induced by m-trifluoromethylphenylpiperazine (TFMPP) and m-chlorophenylpiperazine (m-CPP). J. Neural Transm., Parkinson's Dis. Dement. Sect. 1:1989;207-218.
96. Knapp D.J., Benjamin D., Pohorecky L.A. Effects of gepirone on ethanol consumption, exploratory behavior, and motor performance in rats. Drug Dev. Res. 26:1992;319-341.
97. Kopp C., Misslin R., Vogel E., Rettori M.C., Delagrange P., Guardiola-Lemaître B. Effects of day-length variations on emotional responses toward unfamiliarity in Swiss mice. Behav. Proc. 41:1997;151-157.
98. Kumar K.B., Karanth K.S. Alpha-helical CRF blocks differential influence of corticotropin releasing factor (CRF) on appetitive and aversive memory retrieval in rats. J. Neural Transm. 103:1996;1117-1126.
99. Lambadjieva N.D. Influence of testosterone on some behavioral reactions of male immature rats. Methods Find. Exp. Clin. Pharmacol. 20:1998;673-677.
100. Lambadjieva N.D. Influence of testosterone on some behavioral reactions of male immature rats exposed to continual light. Methods Find. Exp. Clin. Pharmacol. 21:1999;17-20.
101. Laviola G., Pick C.G., Yanai J., Alleva E. Eight-arm maze performance, neophobia, and hippocampal cholinergic alterations after prenatal oxazepam in mice. Brain Res. Bull. 29:1992;609-616.
102. Lee E.H., Tsai M.J. The hippocampus and amygdala mediate the locomotor stimulating effects of corticotropin-releasing factor in mice. Behav. Neural Biol. 51:1989;412-423.
103. Lee E.H., Tang Y.P., Chai C.Y. Stress and corticotropin-releasing factor potentiate center region activity of mice in an open field. Psychopharmacology (Berl.). 93:1987;320-323.
104. Liang K.C., Lee E.H. Intra-amygdala injections of corticotropin releasing factor facilitate inhibitory avoidance learning and reduce exploratory behavior in rats. Psychopharmacology (Berl.). 96:1988;232-236.
105. Lopez F., Miller L.G., Greenblatt D.J., Paul S.M., Shader R.I. Low-dose alprazolam augments motor activity in mice. Pharmacol. Biochem. Behav. 30:1988;511-513.
106. Lopez F., Miller L.G., Greenblatt D.J., Schatzki A., Lumpkin M., Shader R.I. Chronic low-dose alprazolam augments gamma-aminobutyric acid(A) receptor function. J. Clin. Psychopharmacol. 12:1992;119-123.
107. Lucki I., Ward H.R., Frazer A. Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. J. Pharmacol. Exp. Ther. 249:1989;155-164.
108. Mar A., Spreekmeester E., Rochford J. Antidepressants preferentially enhance habituation to novelty in the olfactory bulbectomized rat. Psychopharmacologia. 150:2000;52-60.
109. Marin R.H., Martijena I.D., Arce A. Effect of diazepam and A beta-carboline on open-field and T-maze behaviors in 2-day-old chicks. Pharmacol. Biochem. Behav. 58:1997;915-921.
110. Matsubara K., Matsushita A. Changes in ambulatory activities and muscle relaxation in rats after repeated doses of diazepam. Psychopharmacology. 77:1982;279-283.
111. Matto V., Allikmets L. Acute and chronic citalopram treatment differently modulates rat exploratory behavior in the exploration box test: no evidence for increased anxiety or changes in the [3H]raclopride binding. Pharmacology. 58:1999;59-69.
112. McCarthy M.M., Felzenberg E., Robbins A., Pfaff D.W., Schwartz-Giblin S. Infusions of diazepam and allopregnanolone into the midbrain central gray facilitate open-field behavior and sexual receptivity in female rats. Horm. Behav. 29:1995;279-295.
113. McNamara R.K., Skelton R.W. Like diazepam, CL 218,872, a selective ligand for the benzodiazepine omega 1 receptor subtype, impairs place learning in the Morris water maze. Psychopharmacology. 107:1992;347-351.
114. Meert T.F. Ritanserin overcomes exploratory inhibition induced by cocaine withdrawal. Behav. Pharmacol. 3:1992;149-154.
115. Meert T.F., Colpaert F.C. The shock probe conflict procedure. A new assay responsive to benzodiazepines, barbiturates and related compounds. Psychopharmacology (Berl.). 88:1986;445-450.
116. Meert T.F., Melis W., Aerts N., Clincke G. Antagonism of meta-chlorophenylpiperazine-induced inhibition of exploratory activity in an emergence procedure, the open field test, in rats. Behav. Pharmacol. 8:1997;353-363.
117. Meng I.D., Drugan R.C. Sex differences in open-field behavior in response to the beta-carboline FG 7142 in rats. Physiol. Behav. 54:1993;701-705.
118. Miller L.G., Greenblatt D.J., Roy R.B., Gaver A., Lopez F., Shader R.I. Chronic benzodiazepine administration: III. Upregulation of gamma-aminobutyric acidA receptor binding and function associated with chronic benzodiazepine antagonist administration. J. Pharmacol. Exp. Ther. 248:1989;1096-1101.
119. Miller L.G., Woolverton S., Greenblatt D.J., Lopez F., Roy R.B., Shader R.I. Chronic benzodiazepine administration: IV. Rapid development of tolerance and receptor downregulation associated with alprazolam administration. Biochem. Pharmacol. 38:1989;3773-3777.
120. Miller L.G., Galpern W.R., Greenblatt D.J., Lumpkin M., Shader R.I. Chronic benzodiazepine administration: VI. A partial agonist produces behavioral effects without tolerance or receptor alterations. J. Pharmacol. Exp. Ther. 254:1990;33-38.
121. Misslin R., Cigrang M. Does neophobia necessarily imply fear or anxiety? Behav. Proc. 12:1986;45-50.
122. Moreau J.L., Kilpatrick G., Jenck F. Urocortin, a novel neuropeptide with anxiogenic-like properties. NeuroReport. 8:1997;1697-1701.
123. Moreira E.G., Nascimento N., Rosa G.J., Vassilieff V.S. Crotoxin-induced behavioral effects in rats. Braz. J. Med. Biol. Res. 29:1996;629-632.
124. Moreira E.G., Nascimento N., Rogero J.R., Vassilieff V.S. Gabaergic-benzodiazepine system is involved in the crotoxin-induced anxiogenic effect. Pharmacol. Biochem. Behav. 65:2000;7-13.
125. Moriarty D.D. Anxiogenic effects of a beta-carboline on tonic immobility and open field behavior in chickens (Gallus gallus). Pharmacol. Biochem. Behav. 51:1995;795-798.
126. Nakamura-Palacios E.M., De Oliveira R.W., Gomes C.F. Effects of diazepam or haloperidol on convulsion and behavioral responses induced by bilateral electrical stimulation in the medial prefrontal cortex. Prog. Neuropsychopharmacol. Biol. Psychiatry. 23:1999;1369-1388.
127. Nazar M., Jessa M., Plaznik A. Benzodiazepine-GABAA receptor complex ligands in two models of anxiety. J. Neural. Transm. 104:1997;733-746.
128. Nazar M., Siemiatkowski M., Czonkowska A., Sienkiewicz-Jarosz H., Plaznik A. The role of the hippocampus and 5-HT/GABA interaction in the central effects of benzodiazepine receptor ligands. J. Neural. Transm. 106:1999;369-381.
129. Nazar M., Siemiatkowski M., Bidzinski A., Czlonkowska A., Sienkiewicz-Jarosz H., Plaznik A. The influence of serotonin depletion on rat behavior in the Vogel test and brain 3H-zolpidem binding. J. Neural Transm. 106:1999;355-368.
130. Nobrega J.N., Coscina D.V. Central injections of the GABA-transaminase inhibitor ethanolamine-O-sulfate (EOS): effects on brain [14C]2-deoxy-D-glucose uptake and behavior in rats. Brain Res. 262:1983;243-252.
131. Novas M.L., Wolfman C., Medina J.H., De Robertis E. Proconvulsant and 'anxiogenic' effects of n-butyl beta carboline-3-carboxylate, an endogenous benzodiazepine binding inhibitor from brain. Pharmacol. Biochem. Behav. 30:1988;331-336.
132. O'Connor W.T., Earley B., Leonard B.E. Antidepressant properties of the triazolobenzodiazepines alprazolam and adinazolam: studies on the olfactory bulbectomized rat model of depression. Br. J. Clin. Pharmacol. 19(Suppl. 1):1985;49S-56S.
133. Pähkla R., Harro J., Rago L. Behavioural effects of pinoline in the rat forced swimming, open field and elevated plus-maze tests. Pharmacol. Res. 34:1996;73-78.
134. Panickar K.S., McNaughton N. Comparison of the effects of buspirone and chlordiazepoxide on successive discrimination. Pharmacology Biochemistry and Behavior. 39(2):1991;275-278. (June).
135. Papp M., Przegalinski E. The 5-HT3 receptor antagonists ICS 205-930 and GR38032F, putative anxiolytic drugs, differ from diazepam in their pharmacological profile. J. Psychopharmacol. 3:1989;14-20.
136. Paré A.M.T., Paré W.P., Kluczynski J. Negative affect and voluntary alcohol consumption in Wistar-Kyoto (WKY) and Sprague-Dawley Rats. Physiology & Behavior. 67(2):1999;219-225. (15 August).
137. Plaznik A., Stefanski R., Palejko W., Kostowski W. Serotonergic mechanisms in the nucleus accumbens affected by chronic desipramine treatment. Pharmacol. Biochem. Behav. 39:1991;43-48.
138. Podhorna J., Franklin K.B. Pontine tegmentum lesions increase anxiety-like behavior in rats: a comparison with anxiety produced by beta-CCE. Pharmacol. Biochem. Behav. 65:2000;267-273.
139. Poggioli R., Vergoni A.V., Rasori E., Marrama D., Bertolini A. Behavioral effects of atriopeptin in rats. Neuropeptides. 22:1992;149-154.
140. Pohorecky L.A., Roberts P. Activity in a modified open-field apparatus: effect of diazepam and prenatal stress. Neurotoxicol. Teratol. 13:1991;129-133.
141. Pritchard G.A., Galpern W.R., Lumpkin M., Miller L.G. Chronic benzodiazepine administration: VIII. Receptor upregulation produced by chronic exposure to the inverse agonist FG-7142. J. Pharmacol. Exp. Ther. 258:1991;280-285.
142. Ramanathan M., Jaiswal A.K., Bhattacharya S.K. Differential effects of diazepam on anxiety in streptozotocin induced diabetic and non-diabetic rats. Psychopharmacology (Berl.). 135:1998;361-367.
143. Ramboz S., Oosting R., Amara D.A., Kung H.F., Blier P., Mendelsohn M., Mann J.J., Brunner D., Hen R. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4476-4481.
144. Reddy D.S., Kaur G., Kulkarni S.K. Sigma (sigma1) receptor mediated anti-depressant-like effects of neurosteroids in the Porsolt forced swim test. NeuroReport. 9:1998;3069-3073.
145. Rex A., Stephens D.N., Fink H. "Anxiolytic" action of diazepam and abecarnil in a modified open field test. Pharmacol. Biochem. Behav. 53:1996;1005-1111.
146. Rex A., Voigt J.P., Voits M., Fink H. Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs. Pharmacol. Biochem. Behav. 59:1998;677-683.
147. Rizzi C.A., Prudentino A., Giraldo E. Effects on general behaviour and neurotransmitter functions of a new 5-hydroxytryptamine3 receptor antagonist with potential therapeutic relevance in central nervous system disturbances. Arzneimittelforschung. 43:1993;1033-1041.
148. Salvatierra N.A., Arce A. Day-old chicks categorised on latency to peck, exhibit a stable fear pattern until 15 days of age. Appl. Anim. Behav. Sci. 73:2001;103-116.
149. Sanger D.J., Zivkovic B. Further behavioural evidence for the selective sedative action of zolpidem. Neuropharmacology. 27:1988;1125-1130.
150. Schmitt U., Hiemke C. Combination of open field and elevated plus-maze: a suitable test battery to assess strain as well as treatment differences in rat behavior. Prog. Neuropsychopharmacol. Biol. Psychiatry. 22:1998;1197-1215.
151. Schmitt U., Hiemke C. Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. Behav. Pharmacol. 10:1999;131-137.
152. Schmitt U., Luddens H., Hiemke C. Behavioral effects of GABA(A) receptor stimulation and GABA-transporter inhibition. Pharmacol. Biochem. Behav. 65:2000;351-356.
153. Schmitt U., Luddens H., Hiemke C. Behavioral analysis indicates benzodiazepine-tolerance mediated by the benzodiazepine binding-site at the GABA(A)-receptor. Prog. Neuropsychopharmacol. Biol. Psychiatry. 25:2001;1145-1160.
154. Semeniuk T., Jhangri G.S., Le Melledo J.M. Neuroactive steroid levels in patients with generalized anxiety disorder. J. Neuropsychiatry Clin. Neurosci. 13:2001;396-398.
155. Seredenin S.B., Blednov Yu A., Badyshtov B.A., Gordey M.L., Nagovitsina Y.A. Pharmacogenetic analysis of mechanisms of emotional stress: effects of benzodiazepines. Ann. Ist. Super. Sanita. 26:1990;81-87.
156. Sherif F., Oreland L. Effects of chronic treatment with the GABA-transaminase inhibitor vigabatrin on exploratory behaviour in rats. Behav. Brain Res. 63:1994;11-15.
157. Sherif F., Oreland L. Effect of the GABA-transaminase inhibitor vigabatrin on exploratory behaviour in socially isolated rats. Behav. Brain Res. 72:1995;135-140.
158. Siemiatkowski M., Sienkiewicz-Jarosz H., Czlonkowska A.I., Bidzinski A., Plaznik A. Effects of buspirone, diazepam, and zolpidem on open field behavior, and brain [3H]muscimol binding after buspirone pretreatment. Pharmacol. Biochem. Behav. 66:2000;645-651.
159. Silva M.R., Felicio L.F., Nasello A.G., Bernardi M.M. Is perinatal picrotoxin anxiogenic? Braz. J. Med. Biol. Res. 28:1995;663-666.
160. Singh Y., Jaiswal A.K., Singh M., Bhattacharya S.K. Behavioural effects of prenatal diazepam administration on anxiety patterns in rats. Indian J. Exp. Biol. 34:1996;1095-1099.
161. Skutella T., Probst J.C., Renner U., Holsboer F., Behl C. Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience. 85:1998;795-805.
162. Stefanski R., Palejko W., Kostowski W., Plaznik A. The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety. Neuropharmacology. 31:1992;1251-1258.
163. Stefanski R., Palejko W., Bidzinski A., Kostowski W., Plaznik A. Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of midazolam and 5-HT1A receptor agonists. Neuropharmacology. 32:1993;977-985.
164. Stone E.A., Manavalan S.J., Yi Z., Quartermain D. Beta adrenoceptor blockage mimics effects of stress on motor activity in mice. Neuropsychopharmacology. 12(1):February 1995;65-71.
165. Stratton S.C., Beresford I.J.M., Elliot P.J., Hagan R.M. Behavioural
166. Sutton R.E., Koob G.F., Le Moal M., Rivier J., Vale W. Corticotropin releasing factor produces behavioural activation in rats. Nature. 297:1982;331-333.
167. Taira T., Porkka-Heiskanen T., Korpi E.R. Neonatal administration of a GABA-T inhibitor alters central GABAA receptor mechanisms and alcohol drinking in adult rats. Psychopharmacology. 109:1992;191-197.
168. Taira T., Uusi-Oukari M., Korpi E.R. Early postnatal treatment with muscimol transiently alters brain GABAA receptors and open-field behavior in rat. Eur. J. Pharmacol. 230:1993;307-312.
169. Takahashi L.K., Kalin N.H. Role of corticotropin-releasing factor in mediating the expression of defensive behavior. Blanchard R.J., Brain P.F., Blanchard D.C., Parmigiani S. Ethoexperimental Approaches to the Study of Behavior. NATO ASI Series. 1989;580-594 Kluwer Academic Publishing, Kluwer, Dordrecht, Boston, London.
170. Tashma Z., Raveh L., Liani H., Alkalay D., Givoni S., Kapon J., Cohen G., Alcalay M., Grauer E. Bretazenil, a benzodiazepine receptor partial agonist, as an adjunct in the prophylactic treatment of OP poisoning. J. Appl. Toxicol. 21(Suppl. 1):2001;S115-S119.
171. Thomsen P.H. Obsessive-complusive disorder: pharmacological treatment. Eur. Child Adolesc. Psychiatry. 9:2000;I76-I84. (Suppl.).
172. Ueki S. Behavioral pharmacology of zopiclone. Sleep. 10(Suppl. 1):1987;1-6.
173. Ueki S., Watanabe S., Yamamoto T., Shibata S., Shibata K. Behavioral effects of brotizolam, a new thienotriazolodiazepine derivative. Jpn. J. Pharmacol. 35:1984;287-299.
174. Ueki S., Watanabe S., Fujiwara M., Yamamoto T., Shibata S., Shibata K., Ohta H., Sakurai Y., Iwasaki K., Liou S.Y.et al. Behavioral and electroencephalographic effects of lormetazepam. Nippon Yakurigaku Zasshi. 86:1985;145-163.
175. Uhlenhuth E.H., Matuzas W., Glass R.M., Easton C. Response of panic disorder to fixed doses of alprazolam or imipramine. J. Affect. Disord. 17:1989;261-270.
176. Wagstaff A.J., Cheer S.M., Matheson A.J., Ormrod D., Goa K.L. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs. 62:2002;655-703.
177. Wagstaff A.J., Cheer S.M., Matheson A.J., Ormrod D., Goa K.L. Spotlight on paroxetine in psychiatric disorders in adults. CNS Drugs. 16:2002;425-434.
178. Walsh R.N., Cummins R.A. The open field test: a critical review. Psychol. Bull. 83:1976;481-504.
179. Westenberg H.G. Developments in the drug treatment of panic disorder: what is the place of the selective serotonin reuptake inhibitors? J. Affect. Disord. 40:1996;85-93.
180. Wikinski S.I., Acosta G.B., Gravielle M.C., Bonavita C.D., Bisagno V., Fiszer de Plazas S., Rubio M.C. Diazepam fails to potentiate GABA-induced chloride uptake and to produce anxiolytic-like action in aged rats. Pharmacol. Biochem. Behav. 68:2001;721-727.
181. Williams J.H., Meara J.R., Azmitia E.C. Effects of 5,7-dihydroxytryptamine injections in the fornix-fimbria on locomotor activity in photocell cages and the open field. Behav. Brain Res. 40:1990;37-44.
182. Wong P.T., Ong Y.P. Acute antidepressant-like and antianxiety-like effects of tryptophan in mice. Pharmacology. 62:2001;151-156.
183. Wu H.C., Chen K.Y., Lee W.Y., Lee E.H. Antisense oligonucleotides to corticotropin-releasing factor impair memory retention and increase exploration in rats. Neuroscience. 78:1997;147-153.
184. Yerbury R.E., Cooper S.J. The benzodiazepine partial agonists, Ro16-6028 and Ro17-1812, increase palatable food consumption in nondeprived rats. Pharmacol. Biochem. Behav. 28:1987;427-431.
185. Zorrilla E.P., Schulteis G., Ling N., Koob G.F., De Souza E.B. Performance-enhancing ffects of corticotropin-releasing factor binding protein ligand inhibitors. Soc. Neurosci. Abstr. 24:1998;234.6.